200 related articles for article (PubMed ID: 36437461)
1. Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.
Torres-Duque CA; Ocampo-Gómez J; Castillo MM; Cano-Rosales D; Giraldo-Montoya Á; Rodríguez F; Palacios-Ortega I; Durán-Silva M; Reynales H; García E;
BMC Pulm Med; 2022 Nov; 22(1):447. PubMed ID: 36437461
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
[TBL] [Abstract][Full Text] [Related]
4. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
Schreiber J; Schwab Sauerbeck I; Mailänder C
Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
6. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients.
Arrobas A; Barbosa MP; Rabiais S; Vandewalle B; Félix J
Pulmonology; 2021; 27(2):124-133. PubMed ID: 32247710
[TBL] [Abstract][Full Text] [Related]
9. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
Morales-Múnera O; Pedraza Á; Niño-Serna L
Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
[TBL] [Abstract][Full Text] [Related]
10. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
11. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.
Rojo-Tolosa S; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; González-Gutiérrez MV; Jiménez-Gálvez G; Pérez-Ramírez C; Morales-García C; Jiménez-Morales A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108192
[TBL] [Abstract][Full Text] [Related]
12. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
13. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
[TBL] [Abstract][Full Text] [Related]
14. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018.
MacDonald KM; Kavati A; Ortiz B; Alhossan A; Lee CS; Abraham I
Expert Rev Clin Immunol; 2019 May; 15(5):553-569. PubMed ID: 30763137
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Nieto García A; Garriga-Baraut T; Plaza Martín AM; Nieto Cid M; Torres Borrego J; Folqué Giménez MDM; Lozano Blasco J; Bosque García M; Moreno-Galarraga L; Tortajada-Girbés M; Rivas Juesas C; Penín Antón M; Caballero-Rabasco MA; Gaboli M; López Neyra A; Navarro Morón J; Freixa Benavente A; Valdesoiro Navarrete L; Ballester Asensio E; Sanz Santiago V; Romero García R; Gimeno Díaz de Atauri Á; Valenzuela Soria A; Sánchez Mateos M; Batlles Garrido J; Andrés Martín A; Campos Alonso E; Aragón Fernández C; Vázquez Rodríguez E; Martínez Pardo L; Del-Río Camacho G; Mazón Ramos Á
Pediatr Allergy Immunol; 2021 Jul; 32(5):980-991. PubMed ID: 33619748
[TBL] [Abstract][Full Text] [Related]
16. Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab.
Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Panettieri RA; Corren J
Clin Ther; 2018 Jul; 40(7):1140-1158.e4. PubMed ID: 30049502
[TBL] [Abstract][Full Text] [Related]
17. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
19. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
[TBL] [Abstract][Full Text] [Related]
20. Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance.
Nakamura N; Kashitani Y; Yoshisue H; Nagasaki M; Sasajima T
Allergol Int; 2021 Jul; 70(3):319-326. PubMed ID: 33526351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
